Pregabalin + Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Peripheral Neuropathy
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Trial Timeline
Jan 1, 2007 → Mar 1, 2008
NCT ID
NCT00380874About Pregabalin + Placebo
Pregabalin + Placebo is a approved stage product being developed by Pfizer for Chemotherapy-Induced Peripheral Neuropathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00380874. Target conditions include Chemotherapy-Induced Peripheral Neuropathy.
What happened to similar drugs?
2 of 20 similar drugs in Chemotherapy-Induced Peripheral Neuropathy were approved
Approved (2) Terminated (3) Active (15)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03407430 | Phase 2 | Terminated |
| NCT02607254 | Phase 2 | Completed |
| NCT01701362 | Phase 3 | Completed |
| NCT01387607 | Phase 3 | Completed |
| NCT01455415 | Phase 3 | Completed |
| NCT01432236 | Phase 3 | Completed |
| NCT01271660 | Phase 3 | Completed |
| NCT01271933 | Phase 3 | Completed |
| NCT01270828 | Phase 3 | Completed |
| NCT01049217 | Phase 3 | Terminated |
| NCT00977197 | Phase 2 | Completed |
| NCT00883740 | Phase 3 | Completed |
| NCT00762099 | Approved | UNKNOWN |
| NCT00852436 | Phase 2 | Terminated |
| NCT00994786 | Approved | Completed |
| NCT00631696 | Approved | Completed |
| NCT00584376 | Approved | Completed |
| NCT00380874 | Approved | Terminated |
| NCT00381095 | Approved | Terminated |
| NCT00413010 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Peripheral Neuropathy